Credit Suisse raised the firm’s price target on Eli Lilly to $420 from $400 and keeps an Outperform rating on the shares. Eli Lilly’s sales came in slightly ahead of expectations, and Mounjaro performance more than offset slightly weaker sales of Immunology, Neuroscience, and oncology, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on LLY:
- Eli Lilly price target raised to $440 from $375 at Wells Fargo
- Investors Cheer Eli Lilly’s Obesity Drug Update, Ignore Weak Earnings
- Nektar to regain full rights to Rezpegaldesleukin from Eli Lilly
- Zura Bio announces ZB-106 license from Eli Lilly
- Eli Lilly raises FY23 adjusted EPS view to $8.65-$8.85 from $8.35-$8.55